FIELD: biotechnology.
SUBSTANCE: invention relates specifically to the production of interleukin 10 (IL-10) conjugates, and can be used in medicine for the treatment of cancer. The following is proposed: a modified IL-10 polypeptide containing at an amino acid, which corresponds to the amino acid position, selected from E67, Q70, E74, E75, Q79, N82, K88, K125, N126, N129, K130 and Q132, specified in SEQ ID NO: 1, an azide is a lysine derivative linked to a conjugated moiety, which is a water-soluble polymer, lipid, protein or peptide.
EFFECT: production of modified IL-10 with improved therapeutic characteristics, namely, capable of stimulating pro-inflammatory activity while simultaneously exhibiting antitumor effects.
18 cl, 3 dwg, 2 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| IL-15 CONJUGATES AND THEIR USES | 2019 |
|
RU2793754C2 |
| CYTOKINE CONJUGATES FOR TREATMENT OF AUTOIMMUNE DISEASES | 2018 |
|
RU2787201C2 |
| CYTOKINE CONJUGATES FOR TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES | 2018 |
|
RU2786116C2 |
| CONJUGATE OF ANTIBODY AND DRUG, COMPOSITIONS BASED ON SAID CONJUGATE AND METHODS OF PRODUCING SAID CONJUGATE | 2015 |
|
RU2728235C2 |
| HOMOGENEOUS ANTIBODY AND DRUG CONJUGATES PRODUCED BY ENZYMATIC METHODS | 2015 |
|
RU2796266C2 |
| COMPOSITIONS AND METHODS OF USING FOR TREATING METABOLIC DISORDERS | 2014 |
|
RU2704285C2 |
| ALBUMIN VARIANTS | 2013 |
|
RU2670063C2 |
| CD40L-SPECIFIC CARCASS STRUCTURES DERIVED FROM Tn3, AND METHODS FOR USE THEREOF | 2012 |
|
RU2704992C2 |
| IX PADUA FACTOR ANTIBODIES | 2017 |
|
RU2770006C2 |
| METHOD FOR PURIFYING CONJUGATES BASED ON IL-15/IL-15Rα | 2015 |
|
RU2701301C2 |
